Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:AIMD NASDAQ:HOWL NASDAQ:INKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.02-1.6%$2.82$1.78▼$8.56$64.42M0.9274,145 shs28,976 shsAIMDAinos$3.45+1.8%$3.21$2.00▼$5.00$15.81M2.2586,384 shs62,718 shsHOWLWerewolf Therapeutics$1.45+1.4%$1.30$0.60▼$4.18$65.39M0.64142,116 shs204,934 shsINKTMiNK Therapeutics$14.59+2.2%$17.17$4.56▼$76.00$64.54M0.3344,021 shs22,097 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+1.66%-13.28%+7.34%+32.33%-57.54%AIMDAinos-4.78%-6.09%-2.02%+27.20%+27.97%HOWLWerewolf Therapeutics0.00%+7.52%+7.52%+18.18%-38.89%INKTMiNK Therapeutics-0.90%-9.85%-4.29%+90.52%+84.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.02-1.6%$2.82$1.78▼$8.56$64.42M0.9274,145 shs28,976 shsAIMDAinos$3.45+1.8%$3.21$2.00▼$5.00$15.81M2.2586,384 shs62,718 shsHOWLWerewolf Therapeutics$1.45+1.4%$1.30$0.60▼$4.18$65.39M0.64142,116 shs204,934 shsINKTMiNK Therapeutics$14.59+2.2%$17.17$4.56▼$76.00$64.54M0.3344,021 shs22,097 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+1.66%-13.28%+7.34%+32.33%-57.54%AIMDAinos-4.78%-6.09%-2.02%+27.20%+27.97%HOWLWerewolf Therapeutics0.00%+7.52%+7.52%+18.18%-38.89%INKTMiNK Therapeutics-0.90%-9.85%-4.29%+90.52%+84.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.75Moderate Buy$19.75553.97% UpsideAIMDAinos 0.00N/AN/AN/AHOWLWerewolf Therapeutics 3.00Buy$8.00451.72% UpsideINKTMiNK Therapeutics 2.60Moderate Buy$37.50157.03% UpsideCurrent Analyst Ratings BreakdownLatest AIMD, INKT, ADVM, and HOWL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025HOWLWerewolf TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/25/2025HOWLWerewolf TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.008/21/2025HOWLWerewolf TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$4.00 ➝ $3.008/18/2025INKTMiNK TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$35.00 ➝ $35.008/13/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.007/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/26/2025ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$16.00 ➝ $12.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M63.36N/AN/A$3.40 per share0.89AIMDAinos$110.87K144.95N/AN/A$5.51 per share0.63HOWLWerewolf Therapeutics$1.88M35.27N/AN/A$1.65 per share0.88INKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)AIMDAinos-$14.86M-$4.99N/A∞N/AN/A-108.25%-56.94%11/5/2025 (Estimated)HOWLWerewolf Therapeutics-$70.51M-$1.64N/AN/AN/AN/A-111.87%-62.68%11/6/2025 (Estimated)INKTMiNK Therapeutics-$9.51M-$2.88N/AN/AN/AN/AN/A-227.24%11/13/2025 (Estimated)Latest AIMD, INKT, ADVM, and HOWL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HOWLWerewolf Therapeutics-$0.50-$0.40+$0.10-$0.40$1.50 millionN/A8/14/2025Q2 2025INKTMiNK Therapeutics-$0.55-$1.06-$0.51-$1.06N/AN/A8/13/2025Q2 2025AIMDAinosN/A-$0.99N/A-$0.99N/AN/A8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AAIMDAinosN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A1.541.54AIMDAinos0.962.882.61HOWLWerewolf Therapeutics0.605.305.30INKTMiNK TherapeuticsN/A0.150.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%AIMDAinosN/AHOWLWerewolf Therapeutics64.84%INKTMiNK Therapeutics2.87%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%AIMDAinos10.39%HOWLWerewolf Therapeutics23.60%INKTMiNK Therapeutics22.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableAIMDAinos404.66 million4.17 millionNot OptionableHOWLWerewolf Therapeutics4045.73 million34.94 millionOptionableINKTMiNK Therapeutics304.52 million3.51 millionNo DataAIMD, INKT, ADVM, and HOWL HeadlinesRecent News About These CompaniesMiNK Therapeutics (NASDAQ:INKT) Lowered to Strong Sell Rating by Wall Street ZenAugust 25, 2025 | marketbeat.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 25, 2025 | marketbeat.comB. Riley Reduces Earnings Estimates for MiNK TherapeuticsAugust 24, 2025 | marketbeat.comMiNK Therapeutics (NASDAQ:INKT) Lowered to "Strong Sell" Rating by Zacks ResearchAugust 22, 2025 | marketbeat.comNew Strong Sell Stocks for August 22ndAugust 22, 2025 | zacks.comMiNK Therapeutics (NASDAQ:INKT) Issues Earnings ResultsAugust 16, 2025 | marketbeat.comHC Wainwright & Co. Upgrades MiNK Therapeutics (INKT)August 16, 2025 | msn.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | insidermonkey.comMiNK Therapeutics Reports Q2 2025 Milestones and FinancialsAugust 15, 2025 | msn.comMiNK Therapeutics Extends Cash RunwayAugust 14, 2025 | aol.comAMiNK Therapeutics outlines multiple late-stage catalysts and targets Phase II gastric cancer data by end of 2025 while expanding partnershipsAugust 14, 2025 | msn.comMiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last yearAugust 14, 2025 | msn.comMiNK INKT Q2 2025 Earnings Call TranscriptAugust 14, 2025 | fool.comMiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 ResultsAugust 14, 2025 | globenewswire.comMink Therapeutics Inc News (INKT) - Investing.comAugust 1, 2025 | investing.comMiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial ReportJuly 31, 2025 | globenewswire.comMiNK Therapeutics: Moving Out Of The Hunt's Early DaysJuly 16, 2025 | seekingalpha.comWilliam Blair Downgrades MiNK Therapeutics (INKT)July 16, 2025 | msn.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15, 2025 | globenewswire.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15, 2025 | globenewswire.comMiNK Therapeutics Enters $50M Sales Agreement with B. RileyJuly 15, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, INKT, ADVM, and HOWL Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$3.02 -0.05 (-1.63%) Closing price 04:00 PM EasternExtended Trading$3.03 +0.01 (+0.33%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Ainos NASDAQ:AIMD$3.45 +0.06 (+1.77%) As of 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Werewolf Therapeutics NASDAQ:HOWL$1.45 +0.02 (+1.40%) Closing price 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.MiNK Therapeutics NASDAQ:INKT$14.59 +0.32 (+2.24%) Closing price 04:00 PM EasternExtended Trading$14.86 +0.27 (+1.82%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
